Meeting Banner
Abstract #2369

T1 relaxivity in the bone marrow to monitor response to therapy in acute myeloid leukemia xenografts

Ana L. Gomes1, Diana Passaro1, Dominique Bonnet1, and Bernard Siow2

1Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom, 2In Vivo Imaging, The Francis Crick Institute, London, United Kingdom

Mouse models of cancer are extensively used to better understand the pathobiology of the disease, to test potential novel therapies, and for the development of diagnostic and prognostic imaging tools. Currently, diagnosis of acute myeloid leukemia (AML) is quite invasive. It is based predominantly on blast quantification in the blood and bone marrow (BM) analysis, and imaging is not part of the clinical follow-up of the patients. T1 relaxivity of the mouse BM has not been reported previously. . BM of mice injected with AML cells from patients present higher T1 relaxation values than normal BM, and it further increased after chemotherapy treatment. Although analysis of bigger cohorts of patients would be required, our data suggest a good potential for BM T1 monitoring as a non-invasive marker for AML resistance to therapy.

This abstract and the presentation materials are available to members only; a login is required.

Join Here